未登录

A

Ash Bullement

University of Sheffield

H指数:14

被引数:652

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs

利用外部数据为NICE技术评估中的肿瘤药物总生存期外推提供信息

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-05-240

OA

Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy

西妥昔单抗方案在意大利治疗头颈部鳞状细胞癌的成本效益

FUTURE ONCOLOGY

IF2.6

2025-05-180

OA

De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and Validation (vol 41, pg 1629, 2023)

新发成本-效果模型框架用于非酒精性脂肪性肝炎——建模方法与验证（卷41，页1629，2023）

PHARMACOECONOMICS

IF4.6

2025-03-120

OA

Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach

IF3.4

2024-07-220

OAAI

Don't keep me waiting: estimating the impact of reduced vein-to- vein time on lifetime US 3L+LBCL patient outcomes

IF7.1

2024-06-280

OAAI

Quality-adjusted life-year and life-year estimates for patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the combined positive score 1-19 subgroup treated with pembrolizumab plus /- chemotherapy vs cetuximab-containing regimens

ANNALS OF ONCOLOGY

IF65.4

2023-11-010

PRE

Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland

苏格兰晚期尿路上皮癌的avelumab一线维持治疗的成本-效果分析

FUTURE ONCOLOGY

IF2.6

2023-08-020

OA

A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers

FUTURE ONCOLOGY

IF2.6

2023-04-281

OA

A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment

纳入外部证据以进行基于试验的生存期外推用于卫生技术评估的方法的系统综述

MEDICAL DECISION MAKING

IF2.3

2023-04-264

OAAI

An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2023-02-271

PRE

Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1

VALUE IN HEALTH

IF6

2022-06-019

OAAI

What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2020-12-144

OAAI

Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection

BMC MEDICAL RESEARCH METHODOLOGY

IF3.4

2020-05-0613

OAAI

Stick or Twist? Negotiating Price and Data in an Era of Conditional Approval

VALUE IN HEALTH

IF6

2020-02-011

OAAI

A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2019-09-0440

OAAI

COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES

VALUE IN HEALTH

IF6

2019-05-012

OAAI

REVIEW OF THE APPLICATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA IN RECENT HEALTH TECHNOLOGY ASSESSMENTS (HTAS) OF CANCER IMMUNOTHERAPIES (IOS) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

VALUE IN HEALTH

IF6

2019-05-010

OAAI

SHOULD HEALTH STATE UTILITY VALUES (HSUVS) IN CANCER IMMUNOTHERAPIES (IOS) BE ANALYZED BY TIME TO DEATH (TTD) OR PROGRESSION STATUS? RESULTS OF A SIMULATION STUDY

VALUE IN HEALTH

IF6

2019-05-010

OAAI

Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study

VALUE IN HEALTH

IF6

2019-03-0150

OAAI

ESTIMATED COST SAVINGS FROM DOSE BANDING GUIDANCE: A CASE STUDY USING TREATMENTS FOR STAGE IV MELANOMA

VALUE IN HEALTH

IF6

2018-10-010

OAAI